Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 May 18;82(12):1925–1931. doi: 10.1054/bjoc.2000.1165

A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma

M M Eatock 1, D A Anthony 1, M El-Abassi 2, P Wilson 1, J Paul 1, M Smith 3, M Soukop 4, T R J Evans 1
PMCID: PMC2363246  PMID: 10864199

Abstract

The standard treatment for advanced gastro-oesophageal cancer in the UK is epirubicin, cisplatin and continuous infusion 5-fluoruracil by an indwelling central venous catheter (ECF), which has significant morbidity. Raltitrexed (tomudex), a specific inhibitor of thymidylate synthase with a long plasma terminal half-life (50–100 h) has activity in gastro-intestinal tract malignancy. To reduce the Hickman line-associated morbidity of ECF; we have conducted a dose-finding study of tomudex combined with epirubicin and cisplatin. Twenty-four patients (22 males, two female), median age 63 years (range 21–75), ECOG performance status ≤ 2 with histologically proven, unresectable or metastatic gastric (14 patients), gastro-oesophageal junction (nine patients) or oesophageal (one patient) adenocarcinoma received treatment with 3-weekly cisplatin 60 mg m−2, epirubicin 50 mg m−2and tomudex at doses of 2 mg m−2, 2.5 mg m−2or 3 mg m−2in successive cohorts. Six patients were treated per dose level with no intra-patient dose escalation. Dose escalation occurred after six patients had completed at least one cycle of chemotherapy at the previous dose level. After defining the maximum tolerated dose a further six patients were treated at the preceding dose level to assess toxicity at the proposed phase II dose. A total of 102 cycles (50% completed 6 cycles) were administered. The dose-limiting toxicities are neutropenia and diarrhoea occurring in 2/6 patients at the 3 mg m−2dose level. Of those patients evaluable for response, there were eight partial and one complete response (overall response rate 38%). The median survival was 9.9 months. ECT is an active regimen in oesophagogastric adenocarcinoma. The recommended dose of tomudex for further study in combination with epirubicin and cisplatin is 2.5 mg m−2. © 2000 Cancer Research Campaign

Keywords: gastro-oesophageal cancer, epirubicin, cisplatin, tomudex, chemotherapy

Full Text

The Full Text of this article is available as a PDF (73.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allum W. H., Powell D. J., McConkey C. C., Fielding J. W. Gastric cancer: a 25-year review. Br J Surg. 1989 Jun;76(6):535–540. doi: 10.1002/bjs.1800760604. [DOI] [PubMed] [Google Scholar]
  2. Bajetta E., Di Bartolomeo M., de Braud F., Bozzetti F., Bochicchio A. M., Comella P., Fagnani D., Farina G., Ferroni C., Franchi R. Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. Eur J Cancer. 1994;30A(5):596–600. doi: 10.1016/0959-8049(94)90527-4. [DOI] [PubMed] [Google Scholar]
  3. Beale P., Judson I., Hanwell J., Berry C., Aherne W., Hickish T., Martin P., Walker M. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol. 1998;42(1):71–76. doi: 10.1007/s002800050787. [DOI] [PubMed] [Google Scholar]
  4. Boku N., Chin K., Hosokawa K., Ohtsu A., Tajiri H., Yoshida S., Yamao T., Kondo H., Shirao K., Shimada Y. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res. 1998 Jun;4(6):1469–1474. [PubMed] [Google Scholar]
  5. Cervantes A., Villar-Grimalt A., Abad A., Antón-Torres A., Belón J., Dorta J., Tres A., Camps C., Fonseca E., Massutí B. 5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol. 1993 Nov;4(9):753–757. doi: 10.1093/oxfordjournals.annonc.a058660. [DOI] [PubMed] [Google Scholar]
  6. Cheng A. L., Yeh K. H., Lin J. T., Hsu C., Liu M. Y. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer. Anticancer Res. 1998 Mar-Apr;18(2B):1267–1272. [PubMed] [Google Scholar]
  7. Clarke S. J., Hanwell J., de Boer M., Planting A., Verweij J., Walker M., Smith R., Jackman A. L., Hughes L. R., Harrap K. R. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol. 1996 May;14(5):1495–1503. doi: 10.1200/JCO.1996.14.5.1495. [DOI] [PubMed] [Google Scholar]
  8. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer. 1998;77 (Suppl 2):15–21. doi: 10.1038/bjc.1998.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Elliott T. E., Moertel C. G., Wieand H. S., Hahn R. G., Gerstner J. B., Tschetter L. K., Mailliard J. A. A phase II study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer. Cancer. 1990 Apr 1;65(7):1491–1494. doi: 10.1002/1097-0142(19900401)65:7<1491::aid-cncr2820650707>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  10. Findlay M., Cunningham D., Norman A., Mansi J., Nicolson M., Hickish T., Nicolson V., Nash A., Sacks N., Ford H. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994 Sep;5(7):609–616. doi: 10.1093/oxfordjournals.annonc.a058932. [DOI] [PubMed] [Google Scholar]
  11. Fliser D., Bischoff I., Hanses A., Block S., Joest M., Ritz E., Mutschler E. Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol. 1999 May;55(3):205–211. doi: 10.1007/s002280050619. [DOI] [PubMed] [Google Scholar]
  12. Gore M. E., Earl H. M., Cassidy J., Tattersall M., Mansi J., Seymour L., Azab M. A phase II study of Tomudex in relapsed epithelial ovarian cancer. Ann Oncol. 1995 Sep;6(7):724–725. doi: 10.1093/oxfordjournals.annonc.a059291. [DOI] [PubMed] [Google Scholar]
  13. Jackman A. L., Kelland L. R., Kimbell R., Brown M., Gibson W., Aherne G. W., Hardcastle A., Boyle F. T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer. 1995 May;71(5):914–924. doi: 10.1038/bjc.1995.178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Johnston P. G., Lenz H. J., Leichman C. G., Danenberg K. D., Allegra C. J., Danenberg P. V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995 Apr 1;55(7):1407–1412. [PubMed] [Google Scholar]
  15. Kelland L. R., Kimbell R., Hardcastle A., Aherne G. W., Jackman A. L. Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines. Eur J Cancer. 1995 Jun;31A(6):981–986. doi: 10.1016/0959-8049(95)00198-0. [DOI] [PubMed] [Google Scholar]
  16. Kondo K., Murase M., Kodera Y., Akiyama S., Ito K., Yokoyama Y., Takagi H., Shirasaka T. Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer. Oncology. 1996 Jan-Feb;53(1):64–67. doi: 10.1159/000227537. [DOI] [PubMed] [Google Scholar]
  17. Lacave A. J., Barón F. J., Antón L. M., Estrada E., De Sande L. M., Palacio I., Esteban E., Gracia J. M., Buesa J. M., Fernández O. A. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol. 1991 Nov-Dec;2(10):751–754. doi: 10.1093/oxfordjournals.annonc.a057858. [DOI] [PubMed] [Google Scholar]
  18. Lenz H. J., Leichman C. G., Danenberg K. D., Danenberg P. V., Groshen S., Cohen H., Laine L., Crookes P., Silberman H., Baranda J. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol. 1996 Jan;14(1):176–182. doi: 10.1200/JCO.1996.14.1.176. [DOI] [PubMed] [Google Scholar]
  19. Meropol N. J., Pazdur R., Vincent M., Willson J. K., Kelsen D. P., Douglass H. O., Jr Phase II study of ZD1694 in patients with advanced gastric cancer. Am J Clin Oncol. 1996 Dec;19(6):628–630. doi: 10.1097/00000421-199612000-00020. [DOI] [PubMed] [Google Scholar]
  20. Metzger R., Leichman C. G., Danenberg K. D., Danenberg P. V., Lenz H. J., Hayashi K., Groshen S., Salonga D., Cohen H., Laine L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998 Jan;16(1):309–316. doi: 10.1200/JCO.1998.16.1.309. [DOI] [PubMed] [Google Scholar]
  21. Pazdur R., Meropol N. J., Casper E. S., Fuchs C., Douglass H. O., Jr, Vincent M., Abbruzzese J. L. Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer. Invest New Drugs. 1996;13(4):355–358. doi: 10.1007/BF00873144. [DOI] [PubMed] [Google Scholar]
  22. Rigg A., Cunningham D., Gore M., Hill M., O'Brien M., Nicolson M., Chang J., Watson M., Norman A., Hill A. A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. Br J Cancer. 1997;75(1):101–105. doi: 10.1038/bjc.1997.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Smith I., Jones A., Spielmann M., Namer M., Green M. D., Bonneterre J., Wander H. E., Hatschek T., Wilking N., Zalcberg J. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer. 1996 Aug;74(3):479–481. doi: 10.1038/bjc.1996.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sparano J. A., Schwartz E. L., Salva K. M., Pizzillo M. F., Wadler S., Wiernik P. H. Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. Am J Clin Oncol. 1990 Oct;13(5):374–378. doi: 10.1097/00000421-199010000-00002. [DOI] [PubMed] [Google Scholar]
  25. Taal B. G., Teller F. G., ten Bokkel Huinink W. W., Boot H., Beijnen J. H., Dubbelman R. Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol. 1994 Jan;5(1):90–92. doi: 10.1093/oxfordjournals.annonc.a058705. [DOI] [PubMed] [Google Scholar]
  26. Webb A., Cunningham D., Scarffe J. H., Harper P., Norman A., Joffe J. K., Hughes M., Mansi J., Findlay M., Hill A. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261–267. doi: 10.1200/JCO.1997.15.1.261. [DOI] [PubMed] [Google Scholar]
  27. Yeh K. H., Shun C. T., Chen C. L., Lin J. T., Lee W. J., Lee P. H., Chen Y. C., Cheng A. L. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer. 1998 May 1;82(9):1626–1631. doi: 10.1002/(sici)1097-0142(19980501)82:9<1626::aid-cncr5>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  28. Zaniboni A., Barni S., Labianca R., Marini G., Pancera G., Giaccon G., Piazza E., Signaroldi A., Legnani W., Luporini G. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer. 1995 Nov 15;76(10):1694–1699. doi: 10.1002/1097-0142(19951115)76:10<1694::aid-cncr2820761004>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES